Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in t...
Ginkgo Bioworks (NYSE: DNA ) layoffs continue today with the cell programming company announcing additional job cuts. The latest update to the Ginkgo Bioworks layoffs reveals that the company is plann...
Ginkgo Bioworks continued its slide from earlier in the week. The company is cutting 25% of its workforce....
Ginkgo Bioworks (NYSE: DNA ) layoffs are coming for 158 of the company's employees and more are on the way. Ginkgo Bioworks has revealed that it's going to be cutting 158 jobs as part of its effort to...
CORALVILLE, Iowa--(BUSINESS WIRE)-- #Amplicon--Advancing virology research: IDT's xGen™ HIV Amplicon Panel consisting of primers designed to cover 99.3% of the HIV genome is now available....
Investing in penny stocks can reward bold, patient investors. But patience can be in short supply when you can just buy NVIDIA (NASDAQ: NVDA ) and sleep well at night....
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Suff...
The stock market continues to climb. But in this case, a rising tide isn't necessarily lifting all boats....
Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (N...
